Scolaris Content Display Scolaris Content Display

Adjuvant anti‐VEGF therapy for overall survival and relapse‐free survival in patients with resected non‐metastatic colorectal cancer

Esta versión no es la más reciente

Table 1. Frequency and five‐5 year overall survival for colorectal cancer

Stage

Frequency

Metastases

5‐ year disease‐free survival

5‐ year overall survival

Usual recommended treatment after surgery

I

39% (I and II)

No

95%

83%

Observation

II

39% (I and II)

No

85%

70%

Consider adjuvant chemotherapy

III

36%

No

69%

58%

Recommend adjuvant chemotherapy (e.g. FOLFOX)

IV

20%

Yes

(0%)

13%

Surgery not possible in most cases

Figuras y tablas -
Table 1. Frequency and five‐5 year overall survival for colorectal cancer